Allergy Therapeutics Tangible Net Worth Ratio
Allergy Therapeutics tangible net worth ratio. Allergy Therapeutics (AGY) has a Tangible Net Worth Ratio of 79.8% as of December 2025. This metric is calculated by deducting intangible assets (GBX860.00K) from net assets (GBX4.25 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Check Allergy Therapeutics (AGY) strategic asset index to assess the company's strategic physical and investment asset allocation.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of Allergy Therapeutics (2003–2024)
Tangible net worth ratio of Allergy Therapeutics from 2003 to 2024. This chart shows how Allergy Therapeutics's Tangible Net Worth Ratio has changed across 20 annual periods from 2003 to 2024. As of December 2025, the ratio stands at 79.8%, reflecting net assets of GBX4.25 Million with intangible assets of GBX860.00K GBX. See AGY current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Allergy Therapeutics Tangible Net Worth Ratio by Year (2003–2024)
Allergy Therapeutics tangible net worth ratio by year from 2003 to 2024. The table below presents the year-by-year Tangible Net Worth Ratio for Allergy Therapeutics from 2003 to 2024, covering 20 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see AGY stock market capitalisation.
| Year | Tangible NW Ratio | Net Assets (GBX) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 63.1% | GBX3.71 Million | GBX1.37 Million | GBX64.83 Million | ▲ +176.0 pp |
| 2023 | -113.0% | GBX2.07 Million | GBX4.40 Million | GBX66.77 Million | ▼ -199.6 pp |
| 2022 | 86.7% | GBX37.77 Million | GBX5.04 Million | GBX72.95 Million | ▼ -3.5 pp |
| 2021 | 90.2% | GBX48.53 Million | GBX4.75 Million | GBX88.09 Million | ▲ +1.0 pp |
| 2020 | 89.2% | GBX43.78 Million | GBX4.74 Million | GBX86.22 Million | ▼ -7.1 pp |
| 2019 | 96.3% | GBX37.56 Million | GBX1.41 Million | GBX68.50 Million | ▲ +2.9 pp |
| 2018 | 93.3% | GBX23.03 Million | GBX1.54 Million | GBX51.02 Million | ▲ +0.2 pp |
| 2017 | 93.1% | GBX29.96 Million | GBX2.07 Million | GBX57.18 Million | ▼ 0.0 pp |
| 2016 | 93.1% | GBX30.32 Million | GBX2.08 Million | GBX56.68 Million | ▼ -1.0 pp |
| 2015 | 94.1% | GBX34.47 Million | GBX2.02 Million | GBX50.70 Million | ▲ +2.7 pp |
| 2014 | 91.4% | GBX15.07 Million | GBX1.29 Million | GBX28.40 Million | ▲ +0.6 pp |
| 2013 | 90.8% | GBX14.67 Million | GBX1.35 Million | GBX28.96 Million | ▲ +5.2 pp |
| 2012 | 85.6% | GBX14.59 Million | GBX2.11 Million | GBX27.75 Million | ▲ +68.8 pp |
| 2011 | 16.7% | GBX2.14 Million | GBX1.78 Million | GBX30.62 Million | ▼ -61.1 pp |
| 2010 | 77.9% | GBX3.89 Million | GBX860.00K | GBX29.11 Million | ▼ -8.6 pp |
| 2007 | 86.5% | GBX8.60 Million | GBX1.16 Million | GBX23.99 Million | ▼ -19.1 pp |
| 2006 | 105.6% | GBX32.70 Million | GBX-1.82 Million | GBX37.88 Million | ▲ +10.3 pp |
| 2005 | 95.3% | GBX20.08 Million | GBX951.00K | GBX26.66 Million | ▲ +52.0 pp |
| 2004 | 43.2% | GBX7.08 Million | GBX4.02 Million | GBX11.23 Million | ▲ +23.1 pp |
| 2003 | 20.1% | GBX5.55 Million | GBX4.43 Million | GBX11.15 Million | — |